Prescribing Guides
Metformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
MedNext Editorial Team | 2026-08-01 | 9 min read
Metformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Metformin is the cornerstone of type 2 diabetes management in India and globally. This guide covers its pharmacology, Indian brand availability, dosing, interactions, monitoring, and high-yield points for NEET PG preparation.
Clinical Pharmacology Overview
Metformin is a biguanide that primarily reduces hepatic glucose production via activation of AMP-activated protein kinase (AMPK). It also enhances peripheral insulin sensitivity and reduces intestinal glucose absorption. Unlike sulfonylureas, metformin does not stimulate insulin secretion and therefore carries minimal risk of hypoglycaemia when used as monotherapy.
Pharmacokinetics: Oral bioavailability is 50-60%. It is not protein-bound and is excreted unchanged by the kidneys via tubular secretion. The plasma half-life is approximately 6 hours. Steady-state concentrations are reached within 24-48 hours.
Indian Brand Names
- Glycomet (USV)
- Glucophage (Franco-Indian Pharmaceuticals)
- Glyciphage (Franco-Indian Pharmaceuticals)
- Obimet (Zydus Cadila)
- Walaphage (Wallace Pharmaceuticals)
Extended-release formulations are available as Glycomet SR, Glucophage XR, and others.
Approved Indications in Indian Clinical Practice
- Type 2 diabetes mellitus as first-line monotherapy
- Type 2 diabetes as part of combination therapy with sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, or insulin
- Polycystic ovary syndrome (off-label but widely used in India for insulin resistance and anovulation)
- Pre-diabetes with high-risk features (off-label)
Dosing in Adults
Immediate-release: Start at 500 mg once or twice daily with meals. Titrate by 500 mg every 1-2 weeks as tolerated. Usual effective dose is 1500-2000 mg per day in divided doses. Maximum: 2550 mg per day.
Extended-release (SR/XR): Start at 500 mg once daily with the evening meal. Titrate by 500 mg weekly. Maximum: 2000 mg once daily.
Gradual dose titration minimises gastrointestinal side effects, which are the most common reason for discontinuation.
Important Drug Interactions
- Iodinated contrast media: withhold metformin 48 hours before and after contrast procedures due to risk of lactic acidosis in the setting of contrast-induced nephropathy
- Alcohol: increased risk of lactic acidosis
- Carbonic anhydrase inhibitors (topiramate, acetazolamide): may increase metformin levels
- Cimetidine: competes for renal tubular secretion, raising metformin levels
- Corticosteroids: antagonise glycaemic control
Side Effects and Monitoring
Common: nausea, diarrhoea, abdominal discomfort, metallic taste. These are dose-related and often resolve with slow titration.
Serious: lactic acidosis (rare but potentially fatal, mainly in patients with renal impairment, hepatic failure, or tissue hypoxia).
Long-term: vitamin B12 deficiency (monitor levels periodically, especially in patients on high doses or with peripheral neuropathy).
Monitoring: HbA1c every 3-6 months, serum creatinine and eGFR at least annually (more frequently if borderline), vitamin B12 levels annually after 3-4 years of use.
Special Populations
Pregnancy: Category B. Not recommended in pregnancy in Indian practice; insulin is preferred. However, some guidelines permit metformin in gestational diabetes when insulin is refused or unavailable.
Renal impairment: Contraindicated if eGFR < 30 mL/min/1.73 m2. Use with caution and dose reduction at eGFR 30-45. No dose adjustment needed above eGFR 45.
Elderly: Start at lower doses. Monitor renal function more frequently as age-related decline in GFR increases accumulation risk.
Hepatic impairment: Avoid in clinical or laboratory evidence of hepatic disease due to impaired lactate clearance.
NEET PG High-Yield Points
- Mechanism: activates AMPK, reduces hepatic gluconeogenesis
- Does NOT cause hypoglycaemia as monotherapy (a recurring MCQ theme)
- Weight-neutral to mildly weight-reducing (unlike sulfonylureas and insulin)
- Lactic acidosis is the most feared adverse effect; associated with renal failure, sepsis, and hypoxia
- Must be withheld before iodinated contrast
- Causes vitamin B12 malabsorption
- Only biguanide in current clinical use (phenformin was withdrawn due to lactic acidosis)
- First-line drug for type 2 DM per ADA, ICMR, and RSSDI guidelines
Indian Regulatory Status
Metformin is a Schedule H drug under the Drugs and Cosmetics Act. It requires a prescription from a registered medical practitioner. It is included in the National List of Essential Medicines (NLEM) of India and is available at Jan Aushadhi centres at subsidised prices.
Frequently Asked Questions
What is the maximum dose of metformin in Indian practice?
The maximum recommended dose is 2550 mg per day in divided doses, though most Indian clinicians cap at 2000 mg per day. Extended-release formulations allow once-daily dosing up to 2000 mg.
Can metformin be used in renal impairment?
Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m2. Between 30 and 45, it should be used with caution at reduced doses. Regular monitoring of renal function is essential.
Which Indian brands of metformin are commonly prescribed?
Common Indian brands include Glycomet (USV), Glucophage (Franco-Indian), Obimet (Zydus), Walaphage (Wallace), and Glyciphage (Franco-Indian). Generic metformin is also widely available.
Why is metformin considered first-line for type 2 diabetes?
Metformin reduces hepatic glucose output without causing hypoglycaemia, promotes modest weight loss, has cardiovascular benefit (UKPDS data), is inexpensive, and has decades of safety data. Indian and international guidelines both endorse it as initial monotherapy.
What is the NEET PG significance of metformin?
High-yield topics include its mechanism (AMPK activation), lactic acidosis risk, contraindications in renal and hepatic impairment, weight-neutral to weight-reducing profile, and the requirement to withhold before iodinated contrast procedures.
Continue reading
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Prescribing GuidesParacetamol (Acetaminophen) Prescribing Guide for Indian Clinical Practice
Essential paracetamol prescribing guide for Indian clinicians covering hepatotoxicity thresholds, dosing, overdose management and NEET PG points.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides